Itolizumab Equillium Reports Positive Phase 2 Data in Ulcerative Colitis

Equillium and Biocon Announce Promising Phase 2 Results for Itolizumab in Moderate to Severe Ulcerative Colitis Equillium a clinical-stage biotechnology company focused on developing novel therapeutics for severe autoimmune and inflammatory disorders, and Biocon Limited a global leader in innovation-driven…









